A Phase 3 clinical trial involving leptin was registered as of August 6, 2026. The trial, titled "Micronutrient Enhancement for Development and Health in Adolescents - The MEDHA Study," is listed under identifier NCT07695883.
According to the registration, the study status is currently not yet recruiting. The trial is designated as Phase 3.
No participant enrollment has begun as of the listed date. No outcomes, efficacy data, or safety results have been posted for this trial at this stage. The registration reflects only the planned scope and phase of the study as described in the record.
Leptin is currently classified as an approved compound. This trial update does not by itself change that regulatory status, and no new safety or efficacy conclusions can be drawn from a not-yet-recruiting listing.
Readers interested in tracking this study should refer to the official registration for updates on recruitment status, timelines, or future results. For more background on leptin, see the compound overview.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT07695883"]